Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | QPCT | Q16769 | 3/20 | 0.35 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.35 |
| ▸ | MERTK | Q12866 | 1/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 2/20 | 0.35 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.35 |
| ▸ | CPB1 | P15086 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | ALPG | P10696 | 1/20 | 0.34 |
| ▸ | NPY1R | P25929 | 1/20 | 0.34 |
| ▸ | NMT1 | P30419 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6173659 | 0.91 | HRH3 (0.39) | SLC6A4BRD4HRH3QPCTGNAO1 | |
| SCHEMBL22302587 | 0.84 | HRH3 (0.43) | KDM4CHRH3QPCTALPLPLAA | |
| SCHEMBL27570031 | 0.83 | KDM4C (0.36) | SLC6A4KDM4CHRH3CPB1CPB2 | |
| SCHEMBL27550395 | 0.83 | KDM4C (0.39) | SLC6A4KDM4CHRH3HTR4MERTK | |
| SCHEMBL22180868 | 0.80 | KDM4C (0.38) | KDM4CQPCTALPLPLAACPB1 | |
| SCHEMBL13681754 | 0.77 | PHF8 (0.37) | SLC6A4BRD4HRH3TLR7 | |
| SCHEMBL24103971 | 0.75 | MAPT (0.35) | KDM4CQPCTALPLPLAACPB1 | |
| SCHEMBL7837812 | 0.74 | HRH3 (0.40) | HRH3QPCTNPY1R | |
| SCHEMBL7837811 | 0.74 | HRH3 (0.40) | HRH3QPCTNPY1R | |
| SCHEMBL8543711 | 0.73 | LMNA (0.39) | SLC6A4BRD4HRH3QPCTMERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251172-A1 | PURINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. | 2011-10-13 | — | — | US | disclosed |
| US-20110251172-A1 | PURINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. | 2011-10-13 | — | — | US | disclosed |
| WO-2010019392-A1 | PURINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. (US) | 2010-02-18 | — | — | WO | disclosed |
| EP-0705258-B1 | AZOLYL-CYCLIC AMINE DERIVATIVES WITH IMMUNOMODULATORY ACTIVITY | KNOLL AG (DE) | 1998-12-30 | — | — | EP | disclosed |
| WO-1995000507-A1 | AZOLYL-CYCLIC AMINE DERIVATIVES WITH IMMUNOMODULATORY ACTIVITY | KNOLL AG (DE) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251172-A1 | PURINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | BACE1, APP, PSEN1 | SLC6A4 601/4885BRD4 2840/4885KDM4C 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.